selected scholarly activity
-
conferences
- COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS. Value in Health. S428-S428. 2022
- Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study. Blood. 4990-4990. 2021
-
journal articles
- Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021.. The Lancet Public Health. 9:e729-e744. 2024
- Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.. Lancet Neurology. 23:973-1003. 2024
- Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 403:2162-2203. 2024
- Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. The Lancet. 403:2057-2099. 2024
- Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 403:2133-2161. 2024
- Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B. Clinical Respiratory Journal. 2024:CD014544. 2024
- Cytisine for smoking cessation: A systematic review and meta-analysis. Drug and Alcohol Dependence. 251:110936-110936. 2023
- Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis. 7:102228-102228. 2023
- EE476 Cost-Effectiveness of Emicizumab Prophylaxis in Patients with Hemophilia a without Inhibitors. Value in Health. 25:S428-S428. 2022
- Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature. Journal of Thrombosis and Haemostasis. 20:1364-1375. 2022
- Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders. European Journal of Haematology. 108:232-243. 2022
- Non-clotting factor therapies for preventing bleeds in people with hemophilia. Clinical Respiratory Journal. 2021. 2021
- Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. Clinical Respiratory Journal. 2021:CD014201. 2021
- Missed opportunities for pneumococcal vaccinations in high-risk and older adults in the United States. Journal of Infection and Public Health. 13:101-103. 2020
- Relative Clinical and Cost Burden of Community-Acquired Pneumonia Hospitalizations in Older Adults in the United States—A Cross-Sectional Analysis. Vaccines. 6:59-59. 2018